Moreover, cetuximab, an anti-EGFR monoclonal antibody, and/or gefitinib, an ATP-competitive EGFR tyrosine kinase inhibitor (TKI), have been studied in various types of salivary gland carcinoma [4,37-39], but not in SDC. This evidence concerns the gene EGFR and salivary gland carcinoma.